Institute of Biophysics and Cell Engineering  
220072 Minsk, Akademicheskaya str. 27

Biomedical cell product "Human skin fibroblasts"









Linked profile in other language
Elena Кniazeva
+375 17 251 5357
The Institute has developed a biomedical cell product (BCP) "Human skin fibroblasts" and methods of cell therapy for a wide range of human diseases in surgery, combustiology, cosmetology, etc. with its application. The Institute offers services for the treatment of diseases using the developed BCP under an outsourcing agreement.
Fibroblasts are the main cellular component of the skin, providing its homeostasis and morphofunctional organization. Today, these are the most studied cells and constitute a key link in skin biology. They perform a number of diverse and complex functions: they control the composition and structure of the extracellular matrix of the dermis (collagen, elastin, proteoglycans, and structural glycoproteins), ensuring its remodeling and renewal, and also maintain the physiological state of all layers of the skin.

A biomedical cell product (BCP) based on cultured dermal fibroblasts is used to treat chronic non-healing wounds and trophic ulcers, as well as to correct atrophic cicatricial and age-related skin changes. Biomaterial for the production of BCP is a biopsy specimen of a healthy skin area of ​​about 3 – 5 mm.

Local transplantation of cultured dermal fibroblasts with deep skin defects makes it possible to replenish the population of these cells lost during the chronic wound process due to young and functionally active fibroblasts, which begin to synthesize the extracellular matrix, cytokines, and chemokines, mobilize immune cells and apply physical strength for tissue repair. Stimulation of angiogenesis seems to be a key factor for the healing of ulcers formed against the background of microcirculation disorders.

Cell therapy of atrophic and age-related changes in the skin allows you to start the natural processes of remodeling the microstructure of the dermis. After transplantation, cultured dermal fibroblasts are fully integrated into the dermis, maintaining their biosynthetic activity for a long time. As a result of an increase in the synthesis of own collagen and restoration of microcirculation, there is a modification of the architecture of the dermis, an increase in the content of collagen fibers in it, an increase in skin hydration, an increase in its density and thickness.

The Institute offers its clients services for the treatment of diseases using the developed BCP "Human skin fibroblasts" within the framework of an outsourcing agreement.
Advantages and Innovations
The use of BCP in clinical practice increases the effectiveness of existing treatment methods, does not cause complications and side effects.
Stage of development
Already on the market
Funding source
State budged
IPR status
Secret know-how
Sector group

Organization information

R&D institution
Year established
NACE keywords
Q.86.90 - Other human health activities
M.72.11 - Research and experimental development on biotechnology
Already engaged in transnational cooperation
Additional comments
Over the past 10 years, the Institute has carried out a number of international contracts and agreements within the framework of the Framework Programs of the European Union, as well as with leading research centers, foundations, societies:

FP7-HEALTH-2007-4.1-8 «Promotion and facilitation of international cooperation with Eastern European and Central Asian Countries» (EECAlink, Nr. 223359), 2009-2011;

UNESCO № IAP 3240246593/011/027-Minsk « Science Academies in the Central and Eastern Europe and their Role in Knowledge-based Society», 2010-2011;

FP7-PEAPLE-2012-IRSES «Development of Nanotechnology based Biosensors for Agriculture» (PIRSES-GA-2012-318520), 2012-2016;

FP7-PEAPLE-2012-IRSES «EU-Belarus-Russia Network in Nanomaterials-Driven Anti-Cancer Gene Therapy» (PIRSES-GA-2012-316730), 2013-2017;

FP7-PEOPLE-2011-IIF-299194 «Optical real-time imaging of inhibitory GABAA receptors activity using chimeric GABA channel subunit» («ImagingGABA» Nr 299194) 2013-2015;

«INNOVIMMUNE: Baltic Platform for Innovative Immunotherapies», Nr 19806/2016,2016-2018;

NAWA IAP «Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz» (№ PPI/APM/2018/1/00007/U/001) 2019-2020;

H2020-MSCA-RISE-2017 «Novel 1D photonic metal oxide nanostructures for early stage cancer detection» («CanBioSe», Nr 778157) 2018-2021:

The International Organization for Neurochemistry (ISN); Takeda Science Foundation; The Karpilo-Landau Society; Swiss National Science Foundation; University of Eastern Finland; World Federation of Scientists to Support Research, etc.

Information about partnership

Type of partnership considered
Outsourcing agreement
Type and role of partner sought
Consumers interested in receiving services for the treatment of diseases using the developed BCP "Human skin fibroblasts" within the framework of an outsourcing agreement.
Type and size of partner sought
SME <= 10
SME 11-50
SME 51-250


Views: 1543
Statistics since 23.10.2021 00:51:11